DEA Greenlights Magic Mushroom Production for Medical Trials
Published Date: 4/21/2026
Notice
Summary
AJNA Biosciences wants to make big batches of psilocybin and psilocyn, the active stuff in magic mushrooms, for research and clinical trials. If you’re a registered manufacturer or interested party, you can share your thoughts or ask for a hearing by June 22, 2026. This move helps speed up important medical studies but doesn’t allow any other uses of these substances.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
AJNA Seeks Bulk Manufacture of Psilocybin
If you are a researcher or a business that conducts Schedule I clinical research, AJNA Biosciences applied on March 23, 2026 to be registered as a bulk manufacturer of psilocybin (drug code 7437) and psilocyn (drug code 7438), both Schedule I. If granted, the registration would allow AJNA to bulk manufacture these substances to support internal research, clinical trials, and analytical purposes and to distribute them to customers conducting Schedule I clinical research; no other activities would be authorized.
Stakeholders May Comment or Request Hearing
If you are a registered bulk manufacturer or an applicant, you may submit electronic comments or objections on the AJNA application or file a written request for a hearing on or before June 22, 2026 through https://www.regulations.gov. Upon submission you will receive a Comment Tracking Number; comments are not instantly viewable but a tracking number confirms successful submission.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical often linked to illegal drug use—into Schedule I, the strictest drug category. This means anyone making, selling, or using it faces serious legal rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without adding new costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but the registration could speed up important drug studies.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the Schedule I drug list starting May 4, 2026. This means HHC, a synthetic cousin of THC, is clearly controlled as a hallucinogen with a unique code, making rules easier to follow. Anyone making, selling, or using HHC should know it’s officially regulated now, but no new fees or costs are added.
2026-08517 — Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
Starting May 1, 2026, the DEA officially puts four tricky chemicals—4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA—into Schedule I, meaning they’re now illegal to make, sell, or use without special permission. This affects anyone handling these substances, who will face strict rules and possible penalties. The move helps keep dangerous synthetic drugs off the streets and protects public health.
2026-08176 — Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
Starting April 28, 2026, FDA-approved marijuana-based medicines move from the strictest drug category (Schedule I) to a less strict one (Schedule III). This change helps medical marijuana businesses get faster federal permits to make and sell these products legally. Patients and companies benefit from easier access and clearer rules, while the government keeps control to meet international drug laws.
2026-08177 — Schedules of Controlled Substances: Rescheduling of Marijuana
The DEA is planning to move marijuana to Schedule III, which means it’s seen as less risky and easier to access legally. This change affects anyone using, selling, or researching marijuana and kicks off with a public hearing starting June 29, 2026. If you want to join the conversation, you need to sign up by May 28, 2026, so get ready for some big shifts in marijuana rules and opportunities!
Previous / Next Documents
Previous: 2026-07697 — Importer of Controlled Substances Application: VA Cooperative Studies Program
The VA Cooperative Studies Program wants to become an official importer of certain controlled substances like marijuana extracts and THC. This means they’ll be able to bring these substances into the U.S. for research. People who might be affected, like other manufacturers, have until May 21, 2026, to share their thoughts or ask for a hearing.
Next: 2026-07699 — Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just blocked the property of Santiago Hernan Bermudez Tapia from Nicaragua, adding him to a special sanctions list. This means Americans can’t do business with him, and any money or property he has under U.S. control is frozen. The action took effect on April 16, 2026, signaling serious financial restrictions for those involved.